[ET Net News Agency, 4 June 2025] HSBC Global Research raised the target price for Sino
Biopharm (01177) to HKD5.1 from HKD3.8 and maintained the "buy" rating.
The research house said it turns more optimistic on PD-L1's commercial outlook and the
company's innovative transition. (rc)